**Figure S1. Spike-specific IgG production against SARS-CoV-2 in healthy controls.** The anti-spike IgG titers were assessed over time using ELISA, with sampling at baseline (prior to the first dose, pre v1), before the second dose (pre v2), 30 days after the second dose (+30 v2), before the third dose (pre v3), 30 days after the third dose (+30 v3), before the fourth dose (pre v4), and 30 days after the fourth dose (+30 v4). Data are reported in gray for individual subject, and in blue for their mean.

Supplementary Table S1: Variables associated with log-transformed IgG titres at +30 v3 and at +30 v4 (Multiple regression analysis)

| Variable | +30 v3 | | +30 v4 | |
|---|---|---|---|---|
| | Regression coefficient (95% CI) | P | Regression coefficient (95% CI) | P |
| Age | -0.0221 (-0.0776 to 0.0334) | 0.418 | 0.0228 (-0.0396 to 0.0852) | 0.456 |
| Gender (male) | 0.616 (-0.596 to 1.83) | 0.304 | 0.435 (-0.927 to 1.80) | 0.514 |
| Years post transplant | -0.127 (-0.323 to 0.0693) | 0.194 | -0.184 (-0.405 to 0.0361) | 0.097 |
| Immunosuppressive therapy (0/1) | -1.56 (-3.07 to -0.0427) | **0.044** | -0.730 (-2.43 to -0.971) | 0.383 |
| GVHD (0/1) | -1.30 (-3.22 to 0.627) | 0.176 | -0.527 (-2.69 to 1.64) | 0.618 |

Notes: Bold values indicate statistical significance $P \leq 0.05$.